Glioblastoma study: MRI IMAGING
Official title Serial MRI Scans During Radiation Therapy
ClinicalTrials.gov ID: NCT04188535
What this study is testing
- What it's testing
- The study wants to find out if repeated MRI scans can help doctors see how a tumor is reacting to radiation treatment.
- Who it's for
- The study looks for people with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer, or children with glioma.
- What's involved
- Participants will have three MRI scans: one before radiation, one while receiving radiation, and one after treatment. They will also go through a screening visit to check eligibility.
- Time commitment
- The study lasts the duration of the radiation treatment, with three MRI visits spread over that period.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Participants must have a confirmed malignancy requiring radiation therapy.
- Age: 18 years or older except where otherwise specified in subprotocol.
- ECOG performance status ≤2 (Karnofsky ≥60%)
- Ability to understand and the willingness to sign a written informed consent document.
- Any further criteria listed in the specific disease site subprotocol.
You likely can't join if
- Disease-specific exclusion criteria will be specified in a subprotocol.
- For MRI involving contrast, history of allergic reactions attributed to gadolinium-based IV contrast.
- Inability to undergo magnetic resonance imaging (MRI).
See the full eligibility criteria
- Participants must have a confirmed malignancy requiring radiation therapy.
- Age: 18 years or older except where otherwise specified in subprotocol.
- ECOG performance status ≤2 (Karnofsky ≥60%)
- Ability to understand and the willingness to sign a written informed consent document.
- Any further criteria listed in the specific disease site subprotocol.
- (Esophageal cohort) Patients must be considered appropriate candidates for neoadjuvant chemoradiation therapy followed by esophagectomy.
- (Glioblastoma cohort) Patients with a histologically confirmed newly diagnosed intracranial glioblastoma or gliosarcoma who will be undergoing radiation therapy as part of clinical care.
- (Prostate cohort) Patients with localized prostate cancer who are planning to receive androgen deprivation therapy and definitive radiation therapy.
- (Vulvar cohort) Patients with biopsy-proven locally advanced vulvar cancer for which definitive radiotherapy is planned.
- (Pediatric glioma cohort) Patients age 18 or under (patients 18-30 years old are also eligible if the physician determines that based on genetics, the tumor biology is consistent with pediatric high grade glioma).
- (Sarcoma cohort) Patients with a histologically confirmed newly diagnosed high-grade glioma (WHO grade III or IV) who will be undergoing radiation therapy as part of clinical care.
- Disease-specific exclusion criteria will be specified in a subprotocol.
- For MRI involving contrast, history of allergic reactions attributed to gadolinium-based IV contrast. If patient will not receive contrast, this is not applicable and kidney function will not affect eligibility.
- Inability to undergo magnetic resonance imaging (MRI).
The study team makes the final eligibility decision.
Where it is enrolling
- Boston, Massachusetts, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Boston, Massachusetts, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.